<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549
FORM 8-K
Current Report Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): JUNE 8, 2000
MOLECULAR DEVICES CORPORATION
(Exact name of registrant as specified in its charter)
DELAWARE
(State or other jurisdiction of incorporation)
0-27316 94-2914362
(Commission File No.) (IRS Employer Identification No.)
1311 ORLEANS DRIVE
SUNNYVALE, CA 94089
(Address of principal executive offices and zip code)
Registrant's telephone number, including area code: (408) 747-1700
-----------------------
<PAGE> 2
Item 5. Other Events
This Current Report on Form 8-K contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended. The forward-looking
statements contained herein involve risks and uncertainties, including those
relating to the possible inability to complete the merger transaction involving
Molecular Devices Corporation, a Delaware corporation ("Molecular Devices"), and
LJL BioSystems, Inc., a Delaware corporation ("LJL"), as scheduled, or at all,
and those associated with the ability of the combined company to achieve the
anticipated benefits of the merger. Actual results and developments may differ
materially from those described or incorporated by reference in this Report. For
more information about Molecular Devices and risks arising when investing in
Molecular Devices, investors are directed to Molecular Devices' recent SEC
reports, including its Annual Report on Form 10-K for the year ended December
31, 1999, Quarterly Report on Form 10-Q for the quarter ended March 31, 2000 and
final prospectus for its recent public offering filed on May 4, 2000.
On June 8, 2000, Molecular Devices announced that it had entered into a
definitive Agreement and Plan of Merger and Reorganization (the "Merger
Agreement") with LJL. The Merger Agreement contemplates that, subject to the
satisfaction of certain conditions contained therein, including the approval of
the merger referred to therein by the stockholders of Molecular Devices and LJL
and the expiration or early termination of the waiting period under the
Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, Molecular
Devices would acquire LJL in a stock-for-stock transaction, where each share of
LJL common stock would convert into 0.30 of a share of common stock of Molecular
Devices.
The Merger Agreement is attached hereto as Exhibit 2.1.
Molecular Devices' press release, dated June 8, 2000, "Molecular Devices and LJL
BioSystems Agree to Merge" is attached hereto as Exhibit 99.1.
In connection with the execution of the Merger Agreement, certain stockholders
of Molecular Devices each entered into a voting agreement with LJL, the form of
which is attached hereto as Exhibit 99.2. Also, certain stockholders of LJL each
entered into a voting agreement with Molecular Devices, the form of which is
attached hereto as Exhibit 99.3.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits
(c) Exhibits
<TABLE>
<CAPTION>
Exhibit
Number Description
------ -----------
<S> <C>
2.1 Agreement and Plan of Merger and Reorganization, dated June 7, 2000.
99.1 Press Release dated June 8, 2000.
99.2 Form of Parent Voting Agreement.
99.3 Form of Company Voting Agreement.
</TABLE>
<PAGE> 3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
MOLECULAR DEVICES CORPORATION
Dated: June 9, 2000 By: /s/ TIMOTHY A. HARKNESS
--------------------------------------------------
Timothy A. Harkness
Vice President of Finance and Chief Financial Officer
<PAGE> 4
INDEX TO EXHIBITS
<TABLE>
<CAPTION>
Exhibit
Number Description
------ -----------
<S> <C>
2.1 Agreement and Plan of Merger and Reorganization, dated June 7, 2000.
99.1 Press Release dated June 8, 2000.
99.2 Form of Parent Voting Agreement.
99.3 Form of Company Voting Agreement.
</TABLE>
